证券代码：002007 证券简称：华兰生物 公告编号：2025-041 华兰生物工程股份有限公司 关于独立董事辞职暨补选第九届董事会 独立董事并调整董事会专门委员会委员的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、关于独立董事辞职的情况说明 华兰生物工程股份有限公司（以下简称"公司"）董事会于近日收到公司独 立董事王云龙先生提交的书面辞职报告。王云龙先生因个人原因申请辞去公司独 立董事、提名委员会、审计委员会委员职务。根据相关法律法规，王云龙先生的 辞职报告将在公司股东会选举产生新任独立董事后生效。 公司独立董事王云龙先生的辞职生效后，其在第九届董事会各专门委员会中 的空缺（第九届董事会提名委员会、审计委员会委员职务）将由张志谦先生接替， 鉴于张志谦先生目前为公司独立董事候选人，尚未当选独立董事，故该事项尚需 经股东会审议通过《关于补选第九届董事会独立董事的议案》方可生效，委员任 期自股东会审议通过之日起至第九届董事会届满之日止。 调整生效后公司第九届董事会各专门委员会的人员构成如下： | 专门委员会名称 | 成员 | 召集人（主任委员） | | ...

证券代码：002007 证券简称：华兰生物 公告编号：2025-045 华兰生物工程股份有限公司 关于召开 2025 年第三次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重 大遗漏。 一、召开会议的基本情况 （1）截止 2025 年 11 月 10 日下午收市时，在中国证券登记结算有限责任公司深圳分公司登记在册的本 公司全体股东有权出席股东会，并可以书面形式委托代理人出席会议和参加表决，该股东代理人不必是 本公司股东，或在网络投票时间内参加网络投票。 1、股东会届次：2025 年第三次临时股东会 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所股票上市规则》《深 圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等法律、行政法规、部门规章、 规范性文件及《公司章程》的有关规定。 4、会议时间： （1）现场会议时间：2025 年 11 月 17 日 14:30 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2025 年 11 月 17 日 9:15-9:25，9:30 ...

证券代码：002007 证券简称：华兰生物 公告编号：2025-039 华兰生物工程股份有限公司 关于第九届董事会第三次会议决议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 华兰生物工程股份有限公司（以下简称"公司"）第九届董事会第三次会议 于 2025 年 10 月 17 日以电话或电子邮件方式发出通知，于 2025 年 10 月 29 日在 公司三楼办公室以通讯表决的方式召开。会议由公司董事长安康先生主持。会议 应到董事 9 名，实到董事 9 名。会议符合《公司法》和《公司章程》的规定。 二、董事会会议审议情况 经与会董事认真审议，形成如下决议： 王云龙先生因个人原因申请辞去公司独立董事、提名委员会委员、审计委员 会委员职务，辞去上述职务后，王云龙先生不在公司担任任何职务。王云龙先生 的原定任期至公司第九届董事会任期届满之日止，王云龙先生的辞职报告将在公 司股东会选举产生新任独立董事后生效。 经公司提名委员会及董事会审核，公司董事会同意补选张志谦先生为公司第 九届董事会独立董事，任期自股东会审议通过之日起至第九届董事会任期 ...

Group 1 - The core viewpoint of the article highlights that Hualan Biological's third-quarter revenue decreased by 14.00% to 1.581 billion yuan, while net profit fell by 44.45% to 269 million yuan [1] - For the first three quarters, the company's revenue was 3.379 billion yuan, representing a decline of 3.20%, and net profit was 784 million yuan, down 15.07% [1]

Financial Performance - The company's revenue for Q3 2025 was CNY 1,580,688,450.84, representing a decrease of 14.00% compared to the same period last year[5] - Net profit attributable to shareholders was CNY 268,563,529.57, down 44.45% year-on-year[5] - Basic earnings per share decreased by 44.64% to CNY 0.1467[5] - Total operating revenue for the current period is ¥3,378,886,377.05, a decrease of 3.2% from ¥3,490,648,261.92 in the previous period[18] - Net profit for the current period is ¥827,700,992.33, down 18.1% from ¥1,011,158,954.78 in the previous period[19] - Basic earnings per share for the current period is ¥0.4291, down from ¥0.5056 in the previous period[19] Assets and Liabilities - Total assets at the end of the reporting period were CNY 16,267,369,607.56, a slight decrease of 0.26% from the end of the previous year[5] - The total assets of the company as of September 30, 2025, amounted to CNY 16,267,369,607.56, a slight decrease from CNY 16,309,951,355.29 at the beginning of the period[15] - Current assets increased to CNY 10,048,714,890.01 from CNY 9,616,191,068.19, reflecting a growth of approximately 4.5%[15] - Total liabilities increased to CNY 3,017,772,127.88 from CNY 2,463,225,371.87, marking an increase of about 22.5%[16] - The company's equity decreased to CNY 13,249,597,479.68 from CNY 13,846,725,983.42, reflecting a decline of approximately 4.3%[16] Cash Flow - Cash flow from investment activities increased by 3871.86% year-on-year, mainly due to a decrease in cash paid for investments[11] - The net cash flow from operating activities is ¥450,628,814.59, slightly down from ¥459,709,426.55 in the previous period[20] - Cash inflow from investment activities decreased to ¥9,673,231,639.89 from ¥18,045,530,207.37 in the previous period[20] - Cash outflow for investment activities was ¥8,936,858,346.82, compared to ¥18,026,990,442.39 in the previous period[20] - Net cash flow from financing activities was -859,196,666.44, compared to -627,795,396.80 in the previous period, indicating a decline in financing activities[21] - The cash and cash equivalents at the end of the period reached 1,686,241,001.06, an increase from 839,732,455.35 at the end of the previous period[21] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 147,902[10] - Cash dividends and interest payments totaled 390,198,653.05, showing the company's commitment to returning value to shareholders[21] Expenses and Financial Ratios - The company's weighted average return on equity was 2.25%, down 1.91% from the previous year[5] - The company experienced a 91.35% increase in financial expenses compared to the same period last year, attributed to reduced interest income[11] - Other income decreased by 55.07% year-on-year, primarily due to a reduction in government subsidies received[11] - The company reported a decrease in research and development expenses to ¥234,642,551.42 from ¥211,913,321.30 in the previous period, indicating a focus on innovation[18] Debt and Obligations - The company reported a 50.32% reduction in short-term borrowings compared to the beginning of the year, primarily due to repayment of maturing credit loans[11] - Short-term borrowings decreased significantly to CNY 447,000,000.00 from CNY 899,730,000.00, a reduction of about 50.3%[16] - The company incurred 1,179,380,000.00 in cash payments for debt repayment, indicating significant debt obligations[21] Accounting and Reporting - The company did not undergo an audit for the third quarter financial report, which may affect the perception of financial reliability[22] - The new accounting standards will be implemented starting in 2025, which may impact future financial reporting[23]

Core Viewpoint - The upcoming flu season in 2025 is expected to be significant, with a different strain circulating compared to last year, leading to lower immunity among the public. Vaccination remains the most effective preventive measure, and there is a noticeable increase in vaccine demand across various regions [1][4][5]. Vaccine Supply and Demand - There is a surge in flu vaccine demand, particularly among parents for their children, leading to situations where appointments are available but vaccines are not [6][8]. - The government procurement price for trivalent vaccines has dropped to a historical low of 5.5 yuan per dose, while the price of quadrivalent vaccines has remained stable [2][12]. - Sanofi, a major overseas player, has resumed supply to the Chinese market after a 10-month hiatus, but this has not significantly impacted the market dynamics as domestic manufacturers continue to dominate [10][11]. Flu Activity and Trends - The flu season may start earlier than in previous years, with reports indicating an increase in flu cases, particularly in southern provinces [3][4]. - The predominant strain this year is H3N2, which poses a higher risk due to lower public immunity compared to last year's H1N1 strain [4][5]. Pricing Dynamics - The price of trivalent vaccines has decreased significantly, while quadrivalent vaccines have stabilized after a previous price war [12][13]. - The procurement prices for government-subsidized vaccines have varied, but the overall trend indicates a potential for future price adjustments due to market conditions [13][14]. Market Competition - The return of Sanofi to the Chinese market raises questions about competitive dynamics, but domestic manufacturers like Sinopharm, Beijing Kexing, and Hualan Biological remain the primary suppliers [10][11]. - The flu vaccine market is characterized as an incremental market with substantial demand, and companies do not view each other strictly as competitors [11]. Recommendations for Public Health - Health authorities continue to recommend annual flu vaccinations as the best preventive measure, alongside personal hygiene practices [5][6]. - Increased public awareness and education about the importance of flu vaccination are essential for improving vaccination rates [13].

Core Points - The restructuring protein concept declined by 1.15%, ranking among the top declines in concept sectors as of the market close on October 23 [1] - Within the restructuring protein sector, major declines were observed in companies such as Haitai Biological, Maiwei Biological, and Yipinhong, while 14 stocks experienced price increases, with *ST Suwu, *ST Wanfang, and Kefu Medical leading the gains at 5.21%, 4.99%, and 2.90% respectively [1] Market Performance - The top-performing concept sectors today included Shenzhen State-Owned Enterprise Reform with a rise of 6.62%, while the restructuring protein sector faced a decline of 1.15% [2] - The restructuring protein sector saw a net outflow of 476 million yuan, with 37 stocks experiencing net outflows, and 6 stocks seeing outflows exceeding 30 million yuan [2] - Maiwei Biological led the net outflow with 69.48 million yuan, followed by Hualan Biological, BeiDa Pharmaceutical, and Zhifei Biological with outflows of 66.43 million yuan, 54.42 million yuan, and 33.70 million yuan respectively [2] Stock Performance - The top stocks with significant net outflows in the restructuring protein sector included: - Maiwei Biological: -5.53% with a turnover rate of 7.46% and a net outflow of 69.48 million yuan - Hualan Biological: -1.41% with a turnover rate of 1.37% and a net outflow of 66.43 million yuan - BeiDa Pharmaceutical: -3.26% with a turnover rate of 1.78% and a net outflow of 54.42 million yuan [3] - Conversely, the stocks with notable net inflows included: - SanSheng Guojian: +0.67% with a net inflow of 40.98 million yuan - Baipu Sais: +0.17% with a net inflow of 12.23 million yuan - Huiyu Pharmaceutical: +2.96% with a net inflow of 5.71 million yuan [4]

Core Insights - The Biotech Economy Index (970038) closed at 2261.4 points, down 0.81%, with a trading volume of 16.635 billion yuan and a turnover rate of 1.19% [1] - Among the index constituents, 19 stocks rose while 30 stocks fell, with Meihao Medical leading the gainers at 6.53% and Prolo Pharma leading the decliners at 5.41% [1] Index Performance - The Biotech Economy Index experienced a decline of 0.81% on the reporting day [1] - The total market capitalization of the index constituents was significant, with major players like Mindray Medical valued at 266.98 billion yuan [1] Top Constituents - The top ten constituents of the Biotech Economy Index include: - Mindray Medical (13.81% weight, 220.20 yuan, -1.51% change, 2669.80 billion yuan market cap) [1] - Changchun High-tech (5.41% weight, 119.11 yuan, -0.97% change, 485.89 billion yuan market cap) [1] - Kanglong Chemical (4.66% weight, 30.96 yuan, +0.29% change, 550.53 billion yuan market cap) [1] - Other notable constituents include Taige Pharmaceutical, Muyuans, and Aimeike, all within the biotech and healthcare sectors [1] Capital Flow - The net outflow of main funds from the Biotech Economy Index constituents totaled 0.893 billion yuan, while retail investors saw a net inflow of 0.75 billion yuan [1] - Specific stocks like Kanglong Chemical and Meihao Medical experienced varying levels of net inflow and outflow from different investor categories [2]

Market Overview - The biopharmaceutical sector experienced a decline of 0.57% on October 22, with Aopumai leading the drop [1] - The Shanghai Composite Index closed at 3913.76, down 0.07%, while the Shenzhen Component Index closed at 12996.61, down 0.62% [1] Stock Performance - Notable gainers in the biopharmaceutical sector included: - Wendi Pharmaceutical (688488) with a closing price of 14.77, up 4.01% [1] - Dongbao Bio (300239) at 5.78, up 2.66% [1] - Jinke (688670) at 17.03, up 2.59% [1] - Major decliners included: - Aopumai (688293) at 55.19, down 4.40% [2] - Wofu Bio (300357) at 31.63, down 3.18% [2] - Sanofi (688336) at 59.60, down 2.39% [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 192 million yuan from institutional investors, while retail investors contributed a net inflow of 53.82 million yuan [2] - Specific stock capital flows included: - Te Bao Bio (688278) with a net inflow of 19.00 million yuan from institutional investors [3] - Hualan Bio (002007) with a net inflow of 12.05 million yuan from institutional investors [3] - Aopumai (688293) with a net outflow of 4.40% from institutional investors [3]

Core Points - The Bioeconomy Index (970038) closed at 2262.82 points, up 0.08%, with a trading volume of 19.253 billion yuan and a turnover rate of 1.3% [1] - Among the index constituents, 27 stocks rose, with Iwubio leading at a 10.07% increase, while 22 stocks fell, with Yifan Pharmaceutical leading the decline at 4.45% [1] Index Constituents Summary - The top ten constituents of the Bioeconomy Index include: - Mindray Medical (sz300760) with a weight of 13.81%, latest price at 223.47, down 0.90%, and a market cap of 270.944 billion yuan [1] - Changchun High-tech (sz000661) with a weight of 5.41%, latest price at 121.12, down 0.12%, and a market cap of 49.409 billion yuan [1] - Kanglong Chemical (sz300759) with a weight of 4.66%, latest price at 30.56, up 1.76%, and a market cap of 54.342 billion yuan [1] - Shizhu Aoshi (sz002252) with a weight of 4.52%, latest price at 6.67, up 0.15%, and a market cap of 44.275 billion yuan [1] - Biao Ge Shi Medicine (sz300347) with a weight of 4.23%, latest price at 54.08, up 0.95%, and a market cap of 46.564 billion yuan [1] - Shenzhen Technology (sz000021) with a weight of 4.08%, latest price at 27.24, down 0.58%, and a market cap of 42.693 billion yuan [1] - Muyuan Foods (sz002714) with a weight of 3.66%, latest price at 49.48, down 2.25%, and a market cap of 270.298 billion yuan [1] - Aimeike (sz300896) with a weight of 3.44%, latest price at 167.03, down 1.49%, and a market cap of 50.542 billion yuan [1] - Kailai Ying (sz002821) with a weight of 3.23%, latest price at 105.80, up 2.72%, and a market cap of 38.151 billion yuan [1] - Color Egg Therapy (sz002223) with a weight of 3.19%, latest price at 36.65, down 1.24%, and a market cap of 36.741 billion yuan [1] Capital Flow Summary - The Bioeconomy Index constituents experienced a net outflow of 599 million yuan from institutional investors and 215 million yuan from retail investors, while retail investors saw a net inflow of 814 million yuan [3] - Notable capital flows include: - Kanglong Chemical saw a net inflow of 74.766 million yuan from institutional investors, while retail investors experienced a net outflow of 49.703 million yuan [3] - Hualan Biological had a net inflow of 42.164 million yuan from institutional investors, with retail investors seeing a net outflow of 33.5328 million yuan [3] - Lepu Medical had a net inflow of 40.927 million yuan from institutional investors, while retail investors had a net outflow of 32.1814 million yuan [3] - Kailai Ying had a net inflow of 38.867 million yuan from institutional investors, with retail investors experiencing a net outflow of 16.4533 million yuan [3] - Iwubio had a net inflow of 23.192 million yuan from institutional investors, while retail investors saw a net outflow of 5.9208 million yuan [3]